Phaseline

Companies › Servier Bio-Innovation

Servier Bio-Innovation: clinical trials, targets and expected readouts

6 active drug programs in 8 registered trials: 7 Phase 1, 1 Phase 3; Oncology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ivosidenib
Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
IDH1Phase 3Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen; IDH1-Mutated MalignanciesFeb 2028
S095018
Anti-TIM3 antibody
HAVCR2Phase 1Non-small Cell Lung Cancer (NSCLC)Apr 2027
S095024
Anti-CD73 antibody
NT5EPhase 1Non-small Cell Lung Cancer (NSCLC)Apr 2027
S095029–Phase 1Non-small Cell Lung Cancer (NSCLC); MSI-H/dMMR Gastroesophageal-junction CancerApr 2027
S095035
MAT2A inhibitor
MAT2APhase 1MTAP-deleted Solid TumorsMay 2027
TNG462
PRMT5 inhibitor
PRMT5Phase 1MTAP-deleted Solid TumorsMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06162572S095018Phase 1Non-small Cell Lung Cancer (NSCLC)OncologyApr 2027
NCT06162572S095024Phase 1Non-small Cell Lung Cancer (NSCLC)OncologyApr 2027
NCT06162572S095029Phase 1Non-small Cell Lung Cancer (NSCLC)OncologyApr 2027
NCT06188702S095035Phase 1MTAP-deleted Solid TumorsOncologyMay 2027
NCT06188702TNG462Phase 1MTAP-deleted Solid TumorsOncologyMay 2027
NCT06116136S095029Phase 1MSI-H/dMMR Gastroesophageal-junction CancerOncologyAug 2027
NCT06127407IvosidenibPhase 3Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment RegimenOncologyFeb 2028
NCT07006688IvosidenibPhase 1IDH1-Mutated MalignanciesOncologyJul 2028

Targets

IDH1 (1) HAVCR2 (1) NT5E (1) MAT2A (1) PRMT5 (1)

Companies with the same targets

AstraZeneca Bristol-Myers Squibb Servier Novartis Akeso IDEAYA Biosciences Tango Therapeutics Eli Lilly Nuvation Bio Kissei Pharmaceutical

Companies built like this

IDEAYA Biosciences MediLink Therapeutics (Suzhou) LaNova Medicines Kumquat Biosciences GI Innovation

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.